CorMedix Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
389 INTERPACE PKWY, SUITE 450, PARSIPPANY, NJ, 07054
Mailing Address
389 INTERPACE PKWY, SUITE 450, PARSIPPANY, NJ, 07054
Phone
908-517-9500
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
$163.06M
Net Income
$826.14M
Total Assets
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 6, 2026 | View on SEC |
| 8-K Current report of material events | March 5, 2026 | View on SEC |
| 10-K Annual financial report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | February 6, 2026 | View on SEC |
| 4 Insider stock transaction report | February 6, 2026 | View on SEC |
| 4 Insider stock transaction report | February 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 27, 2026 | View on SEC |
| 4 Insider stock transaction report | January 27, 2026 | View on SEC |
| 4 Insider stock transaction report | January 27, 2026 | View on SEC |
Annual Reports
10-K
March 5, 2026
- CorMedix experienced a transformative year in 2025 with the successful commercial launch of DefenCath and the strategic acquisition of Melinta Therapeutics.
- DefenCath, the first FDA-approved preventative treatment for CRBSIs, demonstrated significant clinical value with up to 71% reduction in CRBSI risk and 70% reduction in hospitalizations.
Insider Trading
STRONG SELL
4 insiders
7 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.